GenSight Biologics S.A.
GenSight Biologics S.A.
- Market cap
- $36.12M
Your view on GSGTF
Overview
What the company does, where it operates, and who runs it.
About GenSight Biologics S.A.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Laurence Rodriguez
- Headquarters
- 74, rue du Faubourg Saint-Antoine, Paris, FR
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Laurence Rodriguez
- Headquarters
- 74, rue du Faubourg Saint-Antoine, Paris, FR
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system.
The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms.
Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration.
The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for GenSight Biologics S.A.. Starting points for GenSight Biologics S.A.: EPS -$0.07, beta 0.74 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for GenSight Biologics S.A.. GenSight Biologics S.A. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for GenSight Biologics S.A.. Trailing twelve-month EPS for GenSight Biologics S.A. stands at -$0.07. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for GenSight Biologics S.A.. GenSight Biologics S.A. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| NEUPNeuphoria Therapeutics Inc. | Healthcare | NASDAQ | $12.7M | ||
| NGNENeurogene Inc. | Healthcare | NASDAQ | $350.0M | ||
| NICXFNicox S.A. | Healthcare | OTC | $30.9M | ||
| NIKINiki BioSolutions, Inc. | Healthcare | NASDAQ | $127,856 | ||
| NKGNNKGen Biotech, Inc. Common Stock | Healthcare | OTC | $2.6M | ||
| NKTRNektar Therapeutics | Healthcare | NASDAQ | $866.4M | ||
| NKTXNkarta, Inc. | Healthcare | NASDAQ | $81.3M | ||
| NMADNOMAD Power Solutions, Inc. | Healthcare | NASDAQ | $31.6M | ||
| NMLSFRestart Life Sciences Corp. | Healthcare | OTC | $3.5M | ||
| NMRANeumora Therapeutics, Inc. Common Stock | Healthcare | NASDAQ | $63.0M | ||
| NMTRQ9 Meters Biopharma, Inc. | Healthcare | OTC | $7,230 | ||
| NNBPNanobac Pharmaceuticals, Incorporated | Healthcare | OTC | $24,951 | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for GenSight Biologics S.A.. Coverage tracks GenSight Biologics S.A. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of GenSight Biologics S.A.